Agonist-biased signaling at the sst2A receptor: The multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways

Molecular Endocrinology

Volumn 24, Issue 1, 2010, Pages 240-249

  Cescato, Renzo ^a   Loesch, Kimberly A ^b   Waser, Beatrice ^a   Mäcke, Helmut R ^c   Rivier, Jean E ^d   Reubi, Jean Claude ^a   Schonbrunn, Agnes ^b,e  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CALCIUM ION; CYCLIC AMP; KE 108; PASIREOTIDE; PERTUSSIS TOXIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CELL LEVEL; CELL STRAIN HEK293; CONTROLLED STUDY; EMBRYO; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; PANCREAS CELL; PRIORITY JOURNAL; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION;

ADENYLATE CYCLASE; ANIMALS; CALCIUM SIGNALING; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GTP-BINDING PROTEINS; HORMONE ANTAGONISTS; HUMANS; PEPTIDES, CYCLIC; PHOSPHORYLATION; PROTEIN ISOFORMS; RATS; RECEPTORS, SOMATOSTATIN; SIGNAL TRANSDUCTION; SOMATOSTATIN; SOMATOSTATIN-SECRETING CELLS; TIME FACTORS;

EID: 73549093367     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0321     Document Type: Article

References (35)

1. Schonbrunn A 2004 Somatostatin receptors. In: Lennarz WJ, Lane MD, eds. Encyclopedia of biological chemistry. Oxford, UK: Elsevier; 55-60
2. Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W 2004 Regulation and function of somatostatin receptors. J Neurochem 89:1057-1091
3. Reubi JC 2003 Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427
4. Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C 2008 Antitumor effects of somatostatin. Mol Cell Endocrinol 286:230-237
5. Körner M, Eltschinger V, Waser B, Schonbrunn A, Reubi JC 2005 Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. Am J Surg Pathol 29:1642-1651
6. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless e 1982 SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31:1133-1140
7. Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, Weckbecker G, Bruns C 2003 A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem 46:2334-2344
8. Schmid HA 2008 Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 286:69-74
9. Reubi JC, Eisenwiener KP, Rink H, Waser B, Mäcke HR 2002 A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 456:45-49
10. Schmid HA, Schoeffter P 2004 Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80(Suppl 1):47-50
11. Liu Q, Cescato R, Dewi DA, Rivier J, Reubi JC, Schonbrunn A 2005 Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Mol Pharmacol 68:90-101
12. Cervia D, Langenegger D, Schuepbach E, Cammalleri M, Schoeffter P, Schmid HA, Bagnoli P, Hoyer D 2005 Binding and functional properties of the novel somatostatin analogue KE 108 at native mouse somatostatin receptors. Neuropharmacology 48:881-893
13. van der Hoek J, van der Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, Boerlin V, Lewis I, Krahnke T, Hofland LJ, Lamberts SW 2005 The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol (Oxf) 63: 176-184
14. Perez DM, Karnik SS 2005 Multiple signaling states of G-protein-coupled receptors. Pharmacol Rev 57:147-161
15. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton PM, Miller KJ, Spedding M, Mailman RB 2007 Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther 320:1-13
16. Kenakin T 2007 Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol 72:1393-1401
17. Schonbrunn A 2008 Selective agonism in somatostatin receptor signaling and regulation. Mol Cell Endocrinol 286:35-39
18. Williams JA 2008 Receptor-mediated signal transduction pathways and the regulation of pancreatic acinar cell function. Curr Opin Gastroenterol 24:573-579
19. 2+ entry in the rat pancreatoma cell line, AR4-2J. Cell Calcium 13:49-58
20. Gu YZ, Brown PJ, Loose-Mitchell DS, Stork PJ, Schonbrunn A 1995 Development and use of a receptor antibody to characterize the interaction between somatostatin receptor subtype 1 and G proteins. Mol Pharmacol 48:1004-1014
21. Gu YZ, Schonbrunn A 1997 Coupling specificity between somatostatin receptor sst2A and G proteins: isolation of the receptor-G protein complex with a receptor antibody. Mol Endocrinol 11:527-537
22. Elberg G, Hipkin RW, Schonbrunn A 2002 Homologous and heterologous regulation of somatostatin receptor 2. Mol Endocrinol 16:2502-2514
23. Brown PJ, Schonbrunn A 1993 Affinity purification of a somatostatin receptor-G-protein complex demonstrates specificity in receptor-G-protein coupling. J Biol Chem 268:6668-6676
24. Liu AM, Wong YH 2005 Activation of nuclear factor κB by somatostatin type 2 receptor in pancreatic acinar AR42J cells involves Gα14 and multiple signaling components: a mechanism requiring protein kinase C, calmodulin-dependent kinase II, ERK, and c-Src. J Biol Chem 280:34617-34625
25. Kaupmann K, Bruns C, Hoyer D, Seuwen K, Lübbert H 1993 Distribution and second messenger coupling of four somatostatin receptor subtypes expressed in brain. FEBS Lett 331:53-59
26. Goldsmith ZG, Dhanasekaran DN 2007 G protein regulation of MAPK networks. Oncogene 26:3122-3142
27. Korzh A, Keren O, Gafni M, Bar-Josef H, Sarne Y 2008 Modulation of extracellular signal-regulated kinase (ERK) by opioid and cannabinoid receptors that are expressed in the same cell. Brain Res 1189:23-32
28. Viguerie N, Tahiri-Jouti N, Ayral AM, Cambillau C, Scemama JL, Bastié MJ, Knuhtsen S, Estève JP, Pradayrol L, Susini C 1989 Direct inhibitory effects of a somatostatin analog, SMS201-995, on AR4-2J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanisms. Endocrinology 124:1017-1025
29. q/11 proteins. Mol Endocrinol 13:2025-2038
30. Samways DS, Henderson G 2006 Opioid elevation of intracellular free calcium: possible mechanisms and physiological relevance. Cell Signal 18:151-161
31. 2+ mobilization in rat AR42J pancreas cells. Biochem Biophys Res Commun 214:81-85
32. s-coupled receptors to the stimulation of phospholipase C. Br J Pharmacol 132:1431-1440
33. Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, Culler M, Ginj M, Liu Q, Schonbrunn A, Reubi JC 2006 Internalization of sst2, sst3 and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med 47:502-511
34. Cescato R, Erchegyi J, Waser B, Piccand V, Maecke HR, Rivier JE, Reubi JC 2008 Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting. J Med Chem 51:4030-4037
35. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Mäcke HR 2000 Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273-282